| Title |
Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, December 2008
|
| DOI | 10.2147/tcrm.s967 |
| Pubmed ID | |
| Authors |
José Luis Callejas-Rubio, Lourdes López-Pérez, Norberto Ortego-Centeno |
| Abstract |
Sarcoidosis is a chronic multisystem disease of unknown etiology, characterized by noncaseating granulomatous infiltration of virtually any organ system. Treatment is often undertaken in an attempt to resolve symptoms or prevent progression to organ failure. Previous studies have suggested a prominent role for tumor necrosis factor-alpha (TNF-alpha) in the inflammatory process seen in sarcoidosis. TNF-alpha and interleukin-1 are released by alveolar macrophages in patients with active lung disease. Corticosteroids have proved to be efficacious in the treatment of sarcoidosis, possibly by suppressing the production of TNF-alpha and other cytokines. Three agents are currently available as specific TNF antagonists: etanercept, infliximab, and adalimumab. Although data from noncomparative trials suggest that all three have comparable therapeutic effects in rheumatoid arthritis, their effects in a granulomatous disease such as sarcoidosis are less consistent. In this review, current data on the effectiveness are summarized. |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Unknown | 59 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 12% |
| Student > Doctoral Student | 6 | 10% |
| Researcher | 6 | 10% |
| Student > Postgraduate | 6 | 10% |
| Student > Bachelor | 5 | 8% |
| Other | 15 | 25% |
| Unknown | 15 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 47% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Nursing and Health Professions | 3 | 5% |
| Agricultural and Biological Sciences | 2 | 3% |
| Business, Management and Accounting | 1 | 2% |
| Other | 6 | 10% |
| Unknown | 17 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2014.
All research outputs
#8,534,528
of 25,373,627 outputs
Outputs from Therapeutics and Clinical Risk Management
#461
of 1,323 outputs
Outputs of similar age
#51,506
of 179,594 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#6
of 18 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,594 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.